시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 판크레리파아제 시장 규모, 점유율, 동향 분석 리포트 : 연령별, 유통경로별, 용도별, 지역별 전망과 예측(2023-2030년)
Global Pancrelipase Market Size, Share & Trends Analysis Report By Age (Adults & Geriatrics, and Children), By Distribution Channel, By Application (Chronic Pancreatitis, Cystic Fibrosis, and Others), By Regional Outlook and Forecast, 2023 - 2030
상품코드 : 1431153
리서치사 : KBV Research
발행일 : 2024년 01월
페이지 정보 : 영문 183 Pages
 라이선스 & 가격 (부가세 별도)
US $ 3,600 ￦ 5,201,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 4,320 ￦ 6,241,000
PDF (Multi User License) help
PDF 보고서를 동일 기업의 10명까지 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,048 ￦ 8,738,000
PDF (Corporate User License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


한글목차

판크레리파아제 시장 규모는 예측 기간 중 CAGR 4.7%로 성장하며, 2030년에는 26억 달러에 달할 것으로 예측되고 있습니다.

그러나 고가의 치료비는 환자, 특히 충분한 보험 혜택을 받지 못하거나 높은 본인 부담금을 부담해야 하는 환자들에게 이 약품에 대한 접근성을 제한할 수 있습니다. 이러한 접근성 제한은 췌장 질환의 최적 관리를 방해할 수 있습니다. 의료 서비스 프로바이더 및 시스템은 특히 많은 수의 췌장 질환 환자를 관리할 때 이 약품의 비용을 충당하기 위해 자원을 배분하는 데 어려움을 겪을 수 있습니다. 이러한 요인으로 인해 향후 수년간 시장 성장이 저해될 것으로 보입니다.

또한 바이러스 확산을 억제하기 위해 시행된 봉쇄, 제한 및 인력 제한으로 인해 제조 공정에 혼란이 발생했습니다. 이러한 도전은 일시적인 제조 시설 폐쇄로 이어져 제제 공급에 영향을 미쳤습니다. 치료 중인 환자의 원격 모니터링은 의료 서비스 프로바이더가 건강 검진이나 임상 검사 없이 치료 효과를 평가하는 한계를 극복해야 하는 어려움에 직면했습니다. 그 결과, COVID-19는 시장에 중간 정도의 영향을 미쳤습니다.

목차

제1장 시장 범위와 조사 방법

제2장 시장 보기

제3장 시장 개요

제4장 세계 시장 : 연령별

제5장 세계 시장 : 유통 채널별

제6장 세계 시장 : 용도별

제7장 세계 시장 : 지역별

제8장 기업 개요

제9장 판크레리파아제 시장의 승리 조건

KSA
영문 목차

영문목차

The Global Pancrelipase Market size is expected to reach $2.6 billion by 2030, rising at a market growth of 4.7% CAGR during the forecast period.

Collaborations between pharmaceutical companies, research institutions, and healthcare organizations on an international scale may foster innovation in medicine's development and distribution in the Asia Pacific. Consequently, the Asia Pacific region would acquire nearly 20% of the total market share by 2030. Growing awareness and emphasis on digestive health contribute to recognizing the importance of managing conditions like pancreatic insufficiency. This awareness can drive both patient's and healthcare providers' demand for the medicine.

Advances in molecular biology and genetic profiling contribute to the emergence of personalized medicine. Tailoring treatment plans based on personal patient characteristics enhances the efficacy of therapy, leading to better outcomes. Data analytics and AI-driven technologies aid in analyzing large datasets, identifying patterns, and predicting disease progression. These tools can assist healthcare professionals in making more informed decisions regarding medicinal dosage adjustments and treatment plans. As a result, the ongoing technological advancements are expected to expand market growth. Additionally, a natural decline in pancreatic function often accompanies aging. This decline may result in reduced secretion of digestive enzymes, leading to conditions such as pancreatic insufficiency. Medicine becomes essential to support digestion in these individuals. Older adults may be more prone to medication-induced pancreatitis, a condition where certain medications can lead to inflammation of the pancreas. This medicine is utilized in the management of pancreatitis, irrespective of its cause. Due to the growing proportion of the aging population, the market is expected to grow significantly.

However, High treatment costs can limit access to this medicine for patients, specifically those without adequate insurance coverage or high out-of-pocket expenses. This restriction in access can lead to suboptimal management of pancreatic disorders. Healthcare providers and systems may face challenges in allocating resources to cover the costs of this medicine, especially when managing a large patient population with pancreatic disorders. Due to the above factors, market growth will be hampered in the coming years.

Moreover, the market experienced disruptions in manufacturing processes due to lockdowns, restrictions, and workforce limitations imposed to curb the spread of the virus. These challenges led to temporary production facility closures, affecting the supply of formulations. Remote monitoring of patients on therapy faced challenges, as healthcare providers had to navigate limitations in assessing treatment effectiveness without physical examinations and laboratory tests. As a result, COVID-19 had a moderate impact on the market.

By Age Analysis

On the basis of age, the market is segmented into children and adults & geriatrics. The children's segment acquired a substantial revenue share in the pancreatic market in 2022. Children with cystic fibrosis often require this medicine to compensate for the reduced pancreatic enzyme production. This medicine helps them digest and absorb essential nutrients from food. Children who undergo pancreatic surgery or experience trauma to the pancreas may have reduced enzyme secretion. Some children may have congenital conditions, such as pancreatic agenesis or malformations, resulting in insufficient enzyme production. The medicine addresses enzyme deficiency and facilitates proper digestion in these cases.

By Distribution Channel Analysis

By distribution channel, the market is classified into online pharmacies, hospital pharmacies, and drug store & retail pharmacies. The online pharmacies segment recorded a remarkable revenue share in the market in 2022. Regulations about the sale and distribution of prescription medications vary between countries. Some online pharmacies operate within stringent regulatory frameworks and adhere to established standards, while others may have looser regulations. Online pharmacies may offer various formulations and dosages of this medicine. Patients should ensure they purchase the specific formulation and dosage their healthcare provider prescribes.

By Application Analysis

Based on application, the market is fragmented into chronic pancreatitis, cystic fibrosis, and others. The cystic fibrosis segment garnered a significant revenue share in the market in 2022. Cystic fibrosis often leads to pancreatic insufficiency, where the pancreas produces insufficient digestive enzymes. This medicine is prescribed to compensate for this deficiency, ensuring proper digestion and absorption of nutrients from food. The medicine is a key component in the nutritional management of individuals with cystic fibrosis. It helps prevent malnutrition by supporting the breakdown of nutrients, allowing for better absorption in the digestive system.

By Regional Analysis

Region-wise, the market is analysed across North America, Europe, Asia Pacific, and LAMEA. In 2022, the North America region witnessed the largest revenue share in the market. Increased awareness among healthcare professionals and patients regarding managing pancreatic insufficiency can drive the demand for this medicine. Education initiatives can lead to early diagnosis and timely initiation of appropriate treatment. Focus on patient-centric approaches, including personalized medicine, can drive the demand for this medicine. Tailoring therapy plans based on individual patient profiles and genetic factors can optimize therapy and improve patient outcomes.

List of Key Companies Profiled

Global Pancrelipase Market Report Segmentation

By Age

By Distribution Channel

By Application

By Geography

Table of Contents

Chapter 1. Market Scope & Methodology

Chapter 2. Market at a Glance

Chapter 3. Market Overview

Chapter 4. Global Pancrelipase Market by Age

Chapter 5. Global Pancrelipase Market by Distribution Channel

Chapter 6. Global Pancrelipase Market by Application

Chapter 7. Global Pancrelipase Market by Region

Chapter 8. Company Profiles

Chapter 9. Winning Imperitives of Pancrelipase Market

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기